Patents by Inventor Edward Leung

Edward Leung has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250050027
    Abstract: A method for preparing a pre-filled multi-chamber injection system includes providing an injection system body, the injection system body defining an open proximal end, a body interior, and an open distal end. The method also includes introducing a first substance into a distal end of the body interior. The method further includes disposing a distal stopper member in the body interior, the distal stopper member and the injection system body defining proximal and distal chambers in the body interior. Moreover, the method includes introducing a second substance into the body interior. In addition, the method includes disposing a proximal stopper member in the body interior. The method also includes inserting an elongate member at least partially into the body interior, the elongate member having a plurality of flow channels for fluidly coupling the proximal and distal chambers. The method further includes coupling a plunger member to the proximal stopper member.
    Type: Application
    Filed: August 15, 2024
    Publication date: February 13, 2025
    Applicant: CREDENCE MEDSYSTEMS, INC.
    Inventors: Jeff Tillack, Alan E. Shluzas, Stephen H. Diaz, Gary Steese-Bradley, John Merhige, Conor Edward Shanley, Mina M. Leung
  • Publication number: 20250054580
    Abstract: A computer-implemented system for determining a genomic testing status of a patient may include at least one processor programmed receive, from a source, unstructured information from a plurality of patient records associated with a patient; determine, using a first machine learning model, a primary patient record from among the plurality of patient records, wherein at least a portion of information represented in the primary patient record correlates to genomic testing; determine, using a second machine learning model and based on unstructured information from one at least one of the patient records, a likelihood of an occurrence of genomic testing for the patient; determine a genomic testing status of the patient based on the determined likelihood of the occurrence of genomic testing; and display a user interface comprising an indicator of the genomic testing status of the patient and a link to the primary patient record.
    Type: Application
    Filed: March 26, 2024
    Publication date: February 13, 2025
    Applicant: Flatiron Health, Inc.
    Inventors: Addison Shelley, Alexander Padmos, Angel Leung, Chun-Che Wang, Dominic Green, Edward Liu, Janet Donegan, Lauren Sutton, Lucy He, Sharang Phadke
  • Publication number: 20110190324
    Abstract: The present invention relates to adenosine A3 receptor antagonists and their use for the prevention and treatment of atherosclerosis by administering to a mammal, in need thereof, a therapeutically effective amount of an adenosine A3 receptor antagonist, or a pharmaceutically acceptable salt thereof, alone or in combination with other anti-atherosclerotic agents.
    Type: Application
    Filed: July 15, 2009
    Publication date: August 4, 2011
    Inventor: Edward Leung
  • Publication number: 20110144027
    Abstract: The present invention relates to pharmaceutical compositions and methods for promoting wound healing. The invention also relates to methods of making pharmaceutical compositions disclosed herein. Pharmaceutical compositions are disclosed comprising an effective amount of a 2-alkoxyadenosine or 2-aralkoxyadenosine, about 10% to about 70% w/w propylene glycol and a thickening agent.
    Type: Application
    Filed: October 17, 2007
    Publication date: June 16, 2011
    Inventors: Edward Leung, Kevin H. Sills, Martin W. Beasley
  • Publication number: 20110118276
    Abstract: The present invention relates to adenosine A2B receptor antagonists and their use for the prevention and treatment of atherosclerosis by administering to a mammal, in need thereof, a therapeutically effective amount of an adenosine A2B receptor antagonist, or a pharmaceutically acceptable salt thereof, alone or in combination with other anti-atherosclerotic agents.
    Type: Application
    Filed: July 15, 2009
    Publication date: May 19, 2011
    Inventor: Edward Leung
  • Publication number: 20090203719
    Abstract: The present invention discloses the use of high affinity adenosine A3 receptor antagonists for enhancing chemotherapeutic treatment of cancers expressing adenosine A3 receptors and cancers expressing P-glycoprotein or MRP. In preferred embodiments, adenosine A3 receptor antagonists are administered before or during administration of a taxane family, vinca alkaloid, camptothecin or antibiotic chemotherapeutic agent.
    Type: Application
    Filed: December 18, 2008
    Publication date: August 13, 2009
    Inventors: Pier Andrea Borea, Pier Giovanni Baraldi, Shih-Fong Chen, Edward Leung
  • Patent number: 7342003
    Abstract: Provided is a method for the synthesis of an aralkyloxyadenosine or an alkoxyadenosine. The method includes protecting the hydroxyl sugar groups with a protecting group to produce a protected halogenated adenosine. The protected halogenated adenosine is alkoxylated, and the hydroxyl sugar groups of the protected halogenated adenosine are deprotected to provide the aralkyloxyadenosine or alkoxyadenosine.
    Type: Grant
    Filed: June 16, 2005
    Date of Patent: March 11, 2008
    Assignee: King Pharmaceuticals Research and Development, Inc.
    Inventors: Allan R. Moorman, Michael Scannell, Thiagarajan Balasubramanian, Russell Outcalt, Edward Leung
  • Publication number: 20070232561
    Abstract: The present invention relates to pharmaceutical compositions and methods for promoting wound healing. The invention also relates to methods of making pharmaceutical compositions disclosed herein. Pharmaceutical compositions are disclosed comprising an effective amount of a 2-alkoxyadenosine or 2-aralkoxyadenosine, about 10% to about 70% w/w propylene glycol and a thickening agent.
    Type: Application
    Filed: March 29, 2007
    Publication date: October 4, 2007
    Inventors: Edward Leung, Kevin H. Sills, Martin W. Beasley
  • Publication number: 20070037179
    Abstract: The invention relates to the diagnosis and prognosis of solid tumors and melanoma by detecting increased cellular levels of A3 receptors in tissue and/or leukocytes obtained from patients with cancer or patients at risk for developing cancer.
    Type: Application
    Filed: January 17, 2006
    Publication date: February 15, 2007
    Inventors: Alberto Liboni, Stefania Gessi, Pier Borea, Steve MacLennan, Edward Leung
  • Publication number: 20060204502
    Abstract: The present invention relates to the use of adenosine receptor antagonists, preferably A3 receptor antagonists, either alone or in combination with other agents for the treatment, prevention and/or management of diseases or disorders associated with overexpression of HIF-1? and/or increased HIF-1? activity (e.g., cancer, respiratory disease). The methods and compositions of the invention are particularly useful for preventing, treating, or ameliorating symptoms associated with a cancer, disease or disorder associated with hypoxia-inducible factor 1? (HIF-1?) using the A3 receptor antagonists of the invention. The present invention provides methods to inhibit the growth of tumors, particularly solid tumors and more particularly hypoxic tumors.
    Type: Application
    Filed: November 22, 2005
    Publication date: September 14, 2006
    Inventors: Pier Borea, Pier Baraldi, Stefania Merighi, Stephen MacLennan, Edward Leung, Allan Moorman
  • Publication number: 20060194756
    Abstract: The present invention relates to the use of adenosine receptor agonists, preferably A3 receptor agonists, either alone or in combination with other agents for the treatment, prevention and/or management of diseases or disorders associated with under-expression of HIF-1? and/or decreased HIF-1 ? activity (e.g., ischemic related disorders). The methods of the invention are directed to methods of reducing tissue damage (e.g., substantially prevention tissue damage, inducing tissue protection) resulting from ischemia orhypoxia. The invention provides methods for treating, preventing and/or ameliorating one or more symptoms of hypoxic or HIF-1? related disorders by administering an A3 receptor agonist either alone or in combination with other agents.
    Type: Application
    Filed: November 22, 2005
    Publication date: August 31, 2006
    Inventors: Pier Borea, Pier Baraldi, Stefania Merighi, Stephen MacLennan, Edward Leung, Allan Moorman
  • Publication number: 20050119289
    Abstract: The present invention discloses the use of high affinity adenosine A3 receptor antagonists for enhancing chemotherapeutic treatment of cancers expressing adenosine A3 receptors and cancers expressing P-glycoprotein or MRP. In preferred embodiments, adenosine A3 receptor antagonists are administered before or during administration of a taxane family, vinca alkaloid, camptothecin or antibiotic chemotherapeutic agent.
    Type: Application
    Filed: June 20, 2003
    Publication date: June 2, 2005
    Inventors: Pier Borea, Pier Baraldi, Shih-Fong Chen, Edward Leung
  • Publication number: 20040067932
    Abstract: The present invention discloses the use of high affinity adenosine A3 receptor antagonists for enhancing chemotherapeutic treatment of cancers expressing adenosine A3 receptors and cancers expressing P-glycoprotein or MRP. In preferred embodiments, adenosine A3 receptor antagonists are administered before or during administration of a taxane family, vinca alkaloid, camptothecin or antibiotic chemotherapeutic agent.
    Type: Application
    Filed: June 24, 2003
    Publication date: April 8, 2004
    Inventors: Pier Andrea Borea, Pier Giovanni Baraldi, Shih-Fong Chen, Edward Leung
  • Publication number: 20030166605
    Abstract: Methods for minimizing ischemic damage and/or reperfusion injury to heart tissue during cardiac surgery where the heart is removed from the body and then re-implanted into the same body, as well as cardiac transplantation, where the heart is removed from one body and transplanted into another body, are disclosed. Prior to removing the heart from the body, adenosine or adenosine A1 or A3 receptor agonists can be administered to the patient in a manner which provides cardioprotection to the heart. When the heart is removed from the body, it can be stored in a cardioplegic solution which contains adenosine, hypoxanthine and/or adenosine A1 or A3 receptor agonists. After the heart is reimplanted or transplanted, reperfusion injury can be minimized by administering adenosine or adenosine A2 receptor agonists to the patient in a manner which minimizes reperfusion injury. Preferably, all three steps are taken in order to minimize the amount of ischemic damage and reperfusion injury to the heart.
    Type: Application
    Filed: December 6, 2002
    Publication date: September 4, 2003
    Inventors: Edward Leung, Roger D. Blevins, Robert M. Mentzer, Victor Molina-Viamonte
  • Patent number: 6489356
    Abstract: The present invention relates to Compound T62, pharmaceutically acceptable salts thereof, and their use in medicine as allosteric adenosine A1 receptor enhancers and uses including treatment of pain, for example, persistent chemical pain, neuropathic pain and acute pain states such as that induced by chemical irritation, gastrointestinal disturbance, migraine and all forms of headache.
    Type: Grant
    Filed: June 18, 2001
    Date of Patent: December 3, 2002
    Inventor: Edward Leung
  • Publication number: 20020055535
    Abstract: The present invention relates to Compound T62, pharmaceutically acceptable salts thereof, and their use in medicine as allosteric adenosine A1 receptor enhancers and uses including treatment of pain, for example, persistent chemical pain, meuropathic pain and acute pain states such as that induced by chemical irritation, gastrointestinal disturbance, migraine and all forms of headache.
    Type: Application
    Filed: June 18, 2001
    Publication date: May 9, 2002
    Inventor: Edward Leung
  • Patent number: D864979
    Type: Grant
    Filed: July 3, 2018
    Date of Patent: October 29, 2019
    Assignee: GOOGLE LLC
    Inventors: Edward Leung Chui Jung, Hélène Park
  • Patent number: D870124
    Type: Grant
    Filed: July 3, 2018
    Date of Patent: December 17, 2019
    Assignee: GOOGLE LLC
    Inventors: Edward Leung Chui Jung, Hélène Park
  • Patent number: D931869
    Type: Grant
    Filed: July 3, 2018
    Date of Patent: September 28, 2021
    Assignee: GOOGLE LLC
    Inventors: Edward Leung Chui Jung, Hélène Park
  • Patent number: D933078
    Type: Grant
    Filed: July 3, 2018
    Date of Patent: October 12, 2021
    Assignee: GOOGLE LLC
    Inventors: Edward Leung Chui Jung, Hélène Park